Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers

Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum–pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous, with outcome...

Полное описание

Библиографические подробности

Главные авторы:	Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2026-02-01
Серии:	Current Oncology
Предметы:	malignant pleural mesothelioma immune checkpoint inhibitors biomarkers tumor microenvironment genomic alterations immunotherapy outcomes
Online-ссылка:	https://www.mdpi.com/1718-7729/33/2/93
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!